MTOR and non-small cell lung carcinoma: Rapamycin, which targets mTOR, was used to verify whether Escherichia-Shigella- and Enterobacteriaceae-derived LPS promoted the inflammatory response and proliferation of NSCLC mainly by activating the mTOR-NF-κB signaling pathway.